Company* |
Company* |
Type/Product Area | Terms/Details (Date) |
Aastrom |
Orthovita Inc. |
Collaboration to develop products for the orthopedics market |
They will use Orthovita's matrices technology with Aastrom's bone marrow-derived cells in the effort; terms were not disclosed (3/20) |
ACE |
Nordic Vaccine A/S* (Denmark) |
Deal to develop fast-acting vaccines that provide better protection and can be delivered in various ways |
ACE will apply Nordic Vaccine's non-alum adjuvants to enhance its vaccines, with initial focus on Campylobacter, the bacterium responsible for travelers' diarrhea (3/8) |
AdipoGenix |
Unigen Pharmaceuticals Inc.* |
Agreement for the joint discovery and development of natural products that target human fat |
They will equally share costs and any profits; AdipoGenix will have rights to resulting pharmaceutical products; Unigen will have rights to cosmeceutical or nutraceutical products (4/6) |
Affimed |
InNexus Biotechnology Inc. (Canada; CDNX:IXS) |
Collaboration to use Affimed's antibodies with InNexus' SuperAntibody antibody enhancement platform |
InNexus will have a right to license one of Affimed's antibodies, while Affimed will have the right to license SuperAntibody technology for one antibody; either would trigger license fees, and potential milestone and royalty payments (4/10) |
Affymetrix |
Iconix Pharmaceuticals Inc.* |
Deal to develop solutions for studying toxicological and pharmacological properties of drugs and drug candidates |
The effort will combine Affymetrix's micro-array technology with Iconix's compound reference database and analysis software; terms were not disclosed (2/7) |
Alnylam |
Integrated DNA Technologies Inc.* |
IDT got nonexclusive rights to provide RNAi research products and services under Alnylam's siRNA patents |
The Kreutzer-Limmer patent family covers small interfering RNAs and their use to mediate RNAi in mammalian cells; terms were not disclosed (2/28) |
AlphaRx Inc. |
Proprius Pharmaceuticals Inc.* |
Proprius got exclusive rights except in Asia and Mexico to AlphaRx's topical NSAID, Indaflex, and backup NSAIDs |
AlphaRx gets $1M up front and could receive up to $116M in milestone payments, as well as double-digit royalties on sales (4/11) |
Angiogen LLC* |
Microbix Biosystems Inc. (Canada; TSE:MBX) |
Deal to commercialize an Angiogen technology that uses urokinase as part of a chemotherapeutic cocktail |
They will jointly pursue a partner for oncology applications; Angiogen would get royalties on resulting sales; Microbix would supply urokinase used in the combination (4/4) |
Aphton Corp. |
Celltrion Inc.* (South Korea) |
Celltrion gained additional rights to the antibodies IGN311 and IGN312 from Aphton subsidiary Igeneon AG |
Celltrion, which had rights in Asia, now has rights in Europe; it also has first right of refusal on the cancer vaccine IGN101; Igeneon gets $5M up front and up to $15M in milestone payments, as well as royalties on any sales (2/7) |
Arisaph |
Undisclosed company |
The unnamed company got nonexclusive rights to dipeptidyl peptidase technology from Arisaph |
The patents cover the use of DPP-IV inhibitors in diabetes applications; Arisaph gets an up- front payment and potential milestone and royalty payments (2/24) |
Arius Research |
Genentech Inc. (NYSE:DNA) |
Genentech got rights to an anticancer antibody and others in the same family |
Arius gets an up-front licensing fee and could get milestone and royalty payments in the deal (3/22) |
AusAm |
Keryx Bio-pharmaceuticals Inc. (KERX) |
Keryx acquired Accumin, a diagnostic product for measuring urinary albumin |
AusAm gets 200,000 Keryx shares, which were valued at about $3.7M; it also will get royalties on sales of the FDA- approved product (3/23) |
AzERx Inc.* |
OrthoLogic Corp. (OLGC) |
OrthoLogic gets exclusive rights to Intracellular Actin Relaxing Molecules technology, including the lead candidate from the class, AZX100 |
AzERx gets $390,000 in cash and 1.355M OrthoLogic shares, which were valued at about $7.7M (2/24) |
Banyan |
CepTor Corp. (OTC BB:CEPO) |
Deal under which Banyan will identify biomarkers for CepTor's Myodur |
Myodur is being developed for Duchenne's muscular dystrophy; terms of the deal were not disclosed (2/7) |
BioInvent |
Immusol Inc.* |
Deal to develop a fully human n-CoDeR antibody for treating age- related macular degeneration and other ophthalmic disorders |
Each company will bring expertise to the collaboration; they will share further costs and revenues (4/3) |
Biolex |
Medarex Inc. (MEDX) |
They expanded deal covering the creation of a commercial line for an undisclosed Medarex monoclonal antibody |
Under the expansion, Biolex will use its LEX System for commercial line creation for two more Medarex antibodies; terms were not disclosed (4/11) |
Bionomics |
Genmab A/S(Denmark; CSE:GEN) |
Genmab got exclusive rights to develop drugs based on a series of angiogenesis targets identified by Bionomics |
Genmab got rights to 8 proteins; Bionomics gets an up-front fee, along with potential clinical and sales milestone payments, and royalties on sales (2/13) |
Biostatin |
Caprion Pharmaceuticals Inc.* |
Caprion acquired a peptide, TT-232 (now CAP-232), that has completed Phase IIa trials in solid tumors |
The product, developed at Biostatin, was licensed from Expergen, a technology transfer and development organization; terms were not disclosed (3/14) |
BioTrove Inc.* |
Blue Sky Biotech Inc.* |
Collaboration to provide screening assays on previously unscreenable drug targets |
BioTrove will provide screening technology and Blue Sky will provide proteins for the mass spectrometry-based high- throughputs creening program (3/20) |
Biovitrum AB* |
Amgen Inc. (AMGN) |
Expanded deal gives Amgen worldwide rights to Biovitrum's small- molecule 11beta-HSD1 enzyme inhibitors for treating metabolic and other diseases |
Amgen already had rights in the Americas, Europe and Australia; Biovitrum gets an up-front payment and potential milestone and royalty payments; it retained co-promotion rights in the Nordic region (2/13) |
Caprion |
Vertex Pharmaceuticals Inc. (VRTX) |
They will use Caprion's proteomics platform to support biomarker discovery at Vertex |
Caprion's Applied BioMedicine group will use samples from Vertex studies in the effort; terms were not disclosed (3/29) |
Celera |
Pharmacyclics Inc. (PCYC) |
Pharmacyclics acquired a number of small-molecule drug candidates for treating cancer and other diseases |
Celera gets $2M up front and between 0.5M and 1M shares of Pharmacyclics stock; it also could get up to $144M in milestone payments, and royalties on resulting sales (4/10) |
Cellumen Inc.* |
Serologicals Corp. (SERO) |
Deal to develop and sell a cytotoxicity profiling panel and services |
Serologicals subsidiary Chemical International Inc. will work with Cellumen in the deal; they would jointly market resulting solutions (2/7) |
Cellectis SA* |
Celonic GmbH* (Germany) |
Celonic got rights to use Cellectis' Meganuclease Recombination System |
The technology will be used to generate I-SceI meganuclease tagged host cell lines for production of biopharmaceuticals; terms were not disclosed (2/21) |
ChemDiv |
Carna Biosciences Inc.* (Japan) |
Deal to develop and market annotated kinase- focused libraries targeting kinases for various pathways and diseases |
The effort combines the expertise of ChemDiv in chemistry and Carna in kinase assay development and profiling; terms were not disclosed (3/30) |
Chimera |
MorphoSys AG (Germany; FSE:MOR) |
Deal to co-market the rapid generation of monoclonal antibodies |
Each will offer the other's services to its customers; the effort includes MorphoSys unit Antibodies by Design and Chimera's Imperacer assay technology (2/20) |
Chiron Corp. |
AVI BioPharma Inc. (AVII) |
AVI got nonexclusive rights to develop and sell antisense drugs against hepatitis C virus |
Chiron gets AVI stock as an initial license payment; further terms were not disclosed (1/27) |
CombinatoRx |
Fovea Pharmaceuticals SA* (France) |
Deal to develop and market combination drugs to treat ophthalmic diseases; also, Fovea licensed rights to preclinical drug combinations to treat diseases of the front of the eye |
Fovea will fund and develop resulting drug combinations through Phase II trials and gets rights in Europe; CombinatoRx gets U.S. rights; for the license, Combinato-Rx is eligible to receive up to $20M in up-front and milestone payments and royalties on sales (1/31) |
Corus PharmaInc.* |
Gilead Sciences Inc. (GILD) |
Gilead is investing $25M in Corus, becoming its second largest shareholder |
Gilead retained an option to purchase the rest of the company, which is in Phase III trials with an inhaled antibiotic (4/12) |
CyGenics Ltd. |
Pharmacell BV* (the Netherlands) |
The companies and three institutions formed a cancer collaboration named PACRIMA |
They plan to develop and mobilize stem cells outside the body; grants are expected to fund most of the work (2/2) |
Diabetica |
Amylin Pharmaceuticals Inc. (AMLN) |
Amylin got exclusive rights to develop glucose- dependent insulinotropic polypeptide agonists |
Diabetica gets an up-front payment and up to $41M in development- and revenue-based milestone payments, as well as royalties on resulting sales (3/7) |
DiaDexus Inc.* |
CFD Therapeutics Inc.* |
Diadexus spun out CFD, which got rights to DiaDexus' therapeutic targets and associated monoclonal antibodies |
Biotechnology Value Fund LP invested in CFD, assuming majority ownership; the antibodies are directed at cancer (3/30) |
DiAthegen |
Phyton Biotech Inc. (unit of DFB Pharmaceuticals Inc.*) |
Phyton got rights to a long- acting growth hormone receptor antagonist for treating various conditions |
DiAthegen is entitled to milestone and royalty payments in the deal; Phyton also gets certain rights to apply DiAthegen's technology to additional protein products (4/11) |
EcoBiotics Ltd.* |
Antisoma plc (UK; LSE:ASM) |
Antisoma will evaluate and has an option to license early stage cancer compounds |
Antisoma will evaluate three compounds and can license two of them; terms of the deal were not disclosed (3/7) |
EiRx |
Almac Diagnostics Ltd.* (UK) |
Companies will use their technologies for research on the molecular basis of colorectal cancer |
The InterTradeIreland INNOVA Collaborative R&D program is providing up to €0.4M to help fund the collaboration (2/9) |
Emisphere |
Genta Inc. (GNTA) |
Deal to use Emisphere's eligen technology to develop an oral formulation of a gallium-containing compound |
Genta will fund work at Emisphere, which also could receive milestone and royalty payments in the deal (3/22) |
Epidauros |
Tm Bioscience Corp. (Canada; TSE:TMC ) |
Tm got a coexclusive license to patents on a biomarker related to the P450-CYP2D6 gene |
Epidauros gets an up-front signing fee and royalties on any sales of P450 Tag-It tests that include the biomarker (3/14) |
Epitomics Inc.* |
Biocare Medical LLC* |
Deal to develop reagent products for the immunohisto- chemistry clinical diagnostic market |
Epitomics will supply rabbit monoclonal antibodies while Biocare will develop test kits; terms of the deal were not disclosed (2/14) |
Evotec AG |
Apeiron Biologics GmbH* (Austria) |
Collaboration to develop small molecules for treating pain, based on a new concept |
The therapeutic concept was developed at the Institute for Molecular Biotechnology in Austria; terms were not disclosed (2/14) |
FivePrime |
Biosite Inc. (BSTE) |
They gained access to each other's technology to evaluate disease targets for potential diagnostic and drug products |
Biosite gets access to certain targets for use in developing diagnostics; FivePrime gets Omniclonal antibodies for certain targets; terms were not disclosed (2/21) |
Galapagos NV |
Arthrogen BV* (the Netherlands) |
Three-year deal to discover targets for gene therapy applications in rheumatoid arthritis |
Galapagos could get up to €7.5M in up-front payments, R&D funding and development milestones; it also would get royalties on resulting sales (3/30) |
Gene-IT* |
Chiron Corp. (CHIR) |
Gene-IT is providing its GenomeQuest service to Chiron |
GenomeQuest is a biological sequence search tool; terms of the deal were not disclosed (2/13) |
Genentech |
Amgen Inc. (AMGN) |
They granted each other licenses related to the manufacture and use of antibodies |
The deal includes a license by Amgen to Genentech's Cabilly patent family on producing immunoglobulins; terms were not disclosed (1/26) |
Genetic |
MetaMorphix Inc.* |
Deal to explore the joint commercialization of various product opportunities |
The companies have had a relationship since 1994; the focus initially will be on genetic tests for livestock and companion animals (1/27) |
Gen-Probe |
Alnylam Pharmaceuticals Inc. (ALNY) |
Alnylam got nonexclusive rights to use Gen-Probe's hybridization protection assay technology |
Alnylam will use the technology in development of therapeutic RNAi molecules; terms of the deal were not disclosed (3/9) |
Immunitor |
MDM Group Inc. (PK:MDDM) |
Collaboration on Immunitor's Amivax vaccine candidate against H5N1 influenza virus |
MDM will focus on marketing alliances to position Amivax for commercialization; Immunitor would get sales royalties; further terms were not disclosed (3/14) |
ImmunoGen |
Millennium Pharmaceuticals Inc. (MLNM) |
They extended for one year deal that gives Millennium access to ImmunoGen technology |
Millennium got rights to test the Tumor-Activated Prodrug technology with antibodies to specific targets; the deal also includes licensing provisions (3/30) |
Inex |
Alnylam Pharmaceuticals Inc. (ALNY) |
Alnylam got an option to exclusively license liposome delivery technology for systemic RNAi therapeutics |
Inex gets option fees and could get license fees, milestone payments and royalties on resulting sales; they also will collaborate to explore liposomal formulations (3/27) |
Inex |
Hana Biosciences Inc. (AMEX:HBX) |
Hana got worldwide rights to three cancer agents: Marqibo, sphingosomal vinorelbine and sphingosomal topotecan |
Inex gets $11.5M in stock and cash up front and up to $30.5M in Hana stock as milestones are met; it also would get royalties on sales (3/17) |
InforSense |
GeneGo Inc.* |
Deal under which they are integrating technologies in the area of systems biology |
Also, GeneGo is joining InforSense's Open Workflow Partner Network (4/11) |
Innovata plc |
CeNeS Pharmaceuticals plc (UK; AIM:CEN) |
CeNeS acquired certain rights covering a synthetic method to manufacture its M6G drug |
M6G is in pivotal trials for treating post- operative pain; terms of the deal were not disclosed (3/6) |
Invitrogen |
DelSite Biotechnologies Inc. (subsidiary of Carrington Laboratories Inc.; CARN) |
Deal to develop a process for a cell-based avian H5 influenza whole virion antigen to be incorporated in DelSite's nasal vaccine product |
The deal will allow DelSite to transition from lab-scale procedures to a scalable manufacturing process in advance of initiating cGMP production; terms were not disclosed (3/1) |
Isis |
ImQuest Pharmaceuticals Inc.* |
ImQuest got exclusive rights to the HIV inhibitor ISIS 5320 |
ImQuest plans to develop the oligonucleotide as a topical microbicide, particularly in the developing world; Isis would get royalties on resulting sales (4/18) |
Isis |
Rosetta Genomics Ltd.* (Israel) |
Deal to discover and develop antisense drugs that regulate microRNAs for treating hepatocellular carcinoma |
They will use Rosetta's database of miRNA genes and Isis' chemistry and antisense expertise in the effort; terms were not disclosed (2/22) |
Isis |
Achaogen* |
Achaogen got rights to Isis' antibiotics-related aminoglycosides program |
Isis get $1.5M of Achaogen stock and potential milestone and royalty payments in the deal (1/31) |
KineMed Inc.* |
Forbes Medi-Tech Inc. (Canada; FMTI) |
Deal to discover non- cardiovascular indications for an undisclosed small- molecule compound from Forbes |
KineMed will screen the compound; Forbes will have the option to develop it in any indications; terms were not disclosed (4/11) |
Lay Line |
BioXell SpA* (Italy) |
Deal to develop and market LLG's preclinical pain product MNAC13, a humanized monoclonal antibody |
LLG gets an up-front payment and potential milestones and royalty payments; BioXell gets exclusive worldwide rights (2/13) |
Luminex |
Tm Bioscience Corp. (Canada; TSE:TMC) |
They extended deal giving Tm rights to commercialize DNA-based molecular diagnostics that operate on Luminex's xMAP platform |
The multiyear expansion replaces the original deal, which expired in March (3/29) |
MaxCyte Inc.* |
Sangamo BioSciences Inc. (SGMO) |
Deal to use MaxCyte's cell- loading system in Sangamo's HIV/CCR5 ZFP therapeutic program |
Maxcyte would supply product and be entitled to clinical and commercial milestone payments; Sangamo also got an option to use MaxCyte's system for ZFP therapeutics in oncology (3/2) |
MaxCyte Inc.* |
Geron Corp. (GERN) |
Geron got rights to use MaxCyte's cell-loading system to manufacture mRNA-loaded dendritic cell-based vaccines |
The deal includes Geron's GRNVAC1 telomerase vaccine; terms were not disclosed (2/15) |
Medarex Inc. |
Diatos SA* (France) |
Diatos acquired full European rights to DTS-201, a doxorubicin prodrug for cancer |
Medarex gets an up-front payment in cash and stock, and potential milestone and royalty payments; Diatos previously had only certain rights in Europe (3/28) |
MethylGene |
Pharmion |
Collaboration to develop and sell MethylGene's histone deacetylase inhibitors in North America, Europe and certain other markets; the deal includes the lead product, MGCD0103 |
MethylGene gets a $20M license fee and a $5M equity investment at a 25% premium up front, giving Pharmion a 7.8% stake in MethylGene; milestone payments to MethylGene for MGCD0103 could reach $145M and up to $100M for other HDAC inhibitors; it also would get royalties on sales; Pharmion will fund 60% of development (1/30) |
MINU LLC* |
Advanced Ocular Systems Ltd. (Australia; ASX:AOS) |
AOS acquired U.S. patent applications covering the ocular use of anti-VEGF agents |
AOS would get more than 80% of commercialization revenues; further terms were not disclosed (2/17) |
MNLpharma |
Avexa Ltd. |
Avexa got rights to a number of HIV integrase inhibitors identified from MNL's library |
MNL is eligible to receive milestone and royalty payment in the deal; terms were not disclosed (2/8) |
MuriGen |
Zenyth |
Deal to develop drugs targeting G-CSF for treating arthritis and other inflammatory diseases |
Zenyth will generate antibodies to the targets from MuriGen; terms of the deal were not disclosed (2/20) |
Nanosyn Inc.* |
Amphora Discovery Corp.* |
Nanosyn will provide chemistry-based services to Amphora for multiple targets |
Nanosyn gets an up-front fee, research funding and potential milestone payments; Amphora will own resulting technology (2/22) |
Novavax Inc. |
Bharat Biotech International Ltd.* (India) |
Deal for the rapid development of pandemic influenza vaccine for India and other south Asian markets |
BBI will fund development of the virus-like particle-based vaccine; Novavax will get access to all resulting data, and would get double-digit royalties on any sales (3/6) |
Optimata Ltd.* |
BioLineRx Ltd.* (Israel) |
Deal to apply Optimata's Virtual Patient technology to BioLineRx's BL-1020 schizophrenia candidate |
They will draw upon Optimata's biomath- ematical and disease- modeling expertise in the deal; terms were not disclosed (2/9) |
Optimer |
Cempra Pharmacecuticals Inc.* |
Cempra got worldwide rights to macrolide/ketolide antibacterial patents |
Optimer gets an equity position in Cempra and is entitled to milestone and royalty payments from resulting drug candidates (4/4) |
Oxford Genome |
Biosite Inc. (BSTE) |
Collaboration to evaluate protein-based disease markers for colorectal cancer |
OGS will identify proteins in samples from patients, and Biosite will have rights to develop diagnostics from them; terms were not disclosed (4/4) |
Oxford |
VIRxSYS Corp.* |
VIRxSYS got rights to use viral envelope technology for gene delivery in production of its VRX496 HIV/AIDS product |
Oxford BioMedica gets an up-front license fee and annual maintenance payments; it also could receive milestone royalty payments (3/10) |
PharmaCell BV* |
CyGenics Ltd. (Australia; ASX:CYN) |
CyGenics is acquiring a significant stake in PharmaCell through an equity investment |
The move gives CyGenics access to the European markets; terms were not disclosed (4/11) |
Pharmacopeia |
Neurocrine Biosciences Inc. (NBIX) |
Pharmacopeia will produce candidates against a disease target from Neurocrine |
Pharmacopeia is entitled to milestone and royalty payments from the deal, which represents an expansion of a collaboration started in 2003 (3/15) |
Praecis |
Gilead Sciences Inc. (GILD) |
Deal under which Praecis will identify lead drug candidates for an antiviral target supplied by Gilead |
Each will fund its own work in the effort; Gilead has an exclusive option to license resulting lead molecules (3/21) |
ProBioGen |
Serono SA (Switzerland; NYSE:SRA) |
Serono will evaluate ProBioGen's human neuronal cell line for producing recombinant proteins |
Terms of the deal were not disclosed (4/5) |
Proteome |
Medical Solutions plc* (UK) |
Co-marketing deal under which they will promote each other's technologies |
The focus is on protein biomarkers for use in diagnostics and drug development programs (3/15) |
Proteome |
Egenix Inc. |
Deal to co-develop a semen- based diagnostic for prostate cancer based on the human carcinoma antigen |
Egenix will provide initial funding; they then will share rights for further development and commercialization (3/7) |
Qiagen NV |
ActiveSight (unit of Rigaku Americas Corp.) |
They entered a co-marketing deal related to protein crystallography for drug discovery |
They seek to ease access to protein crystal- lization reagents and crystallographic services; terms were not disclosed (2/22) |
ReNeuron |
StemCells Inc. (STEM) |
Deal under which ReNeuron will supply cell lines to Stem Cells |
The agreement follows a cross-licensing deal between the companies in 2005 (4/18) |
Retinagenix |
QLT Inc. (Canada; QLTI) |
Exclusive deal to develop synthetic retinoid products for treating degenerative retinal diseases |
Retinagenix is entitled to a $1.5M up-front payment, along with milestone payments and a single-digit royalty on resulting sales (4/5) |
RheoGene |
Ichor Medical Systems Inc.* |
Ichor got rights to use RheoSwitch technology with its electroporation technology for delivery of a gene therapy product for multiple sclerosis |
Ichor also got an option to use the Rheo- Switch Therapeutic System in two additional indications; RheoGene got an option to use Ichor's TriGrid Delivery System in drug development (2/9) |
Rosetta |
Asuragen Inc.* |
Collaboration to develop three prostate cancer diagnostic products |
Terms of the deal were not disclosed (1/20) |
Sareum |
Idenix Pharmaceuticals Inc. (IDIX) |
Sareum will generate lead chemical series, which Idenix will develop into potential drugs for treating hepatitis C |
Sareum is entitled to research fees and milestone payments of up $5M, plus another milestone payment if compounds advance to clinical development (2/9) |
Savient |
Cytogen Corp. (CYTO) |
Letter of intent grants Cytogen exclusive rights in the U.S. to Soltamox, an oral liquid hormonal therapy approved for breast cancer indications |
Savient would get a $2M licensing fee up front,sales-based milestone payments of up to $4M, and royalties on sales (2/8) |
Selexis SA*(Switzerland) |
Henogen SA* (Belgium) |
Henogen gets access to Selexis technology and expertise for cell population generation and cell line development |
Henogen has nonexclusive rights to use the Selexis engineered cell lines to produce proteins and antibodies for R&D and manufacturing purposes (4/11) |
Senetek plc |
Plethora Solutions Holdings plc(UK; AIM:PLE) |
Plethora got North American rights to Invicorp, a combi- nation drug treatment for erectile dysfunction |
Senetek is entitled to milestone and royalty payments; Plethora also got an option to develop the product elsewhere outside of Europe (2/21) |
Signalomics |
Invitrogen Corp. (IVGN) |
Deal to develop nanocrystal reagents for use in cancer diagnostics |
The initial goal is to develop an imaging agent to identify colon carcinomas requiring surgical intervention (4/11) |
Sirius |
Tm Bioscience Corp. (Canada; TSE:TMC) |
Tm got exclusive rights to patents for specific biomarkers related to drugs used to treat severe sepsis |
Sirius gets $4M up front, which will be repaid from earnings on sales of the severe sepsis test; earnings then will be shared equally (3/20) |
Symphogen |
Biovitrum AB* (Sweden) |
Deal to develop and sell Symphogen's Sym001, which is in development for treating certain blood disorders |
Symphogen gets an up-front fee and poten- tial milestone payments, along with rights in the Americas; Biovitrum has rights in Europe, Russia and the Middle East (2/1) |
Syntonix |
Biovitrum AB* (Sweden) |
Deal to develop and sell Syntonix's FIX:Fc, a long-acting recombinant Factor IX preclin- ical product for hemophilia B |
Syntonix gets an up-front payment and equity investment from Biovitrum, which would market the product in Europe, Russia and the Middle East; Syntonix could receive milestone payments; costs and profits will be shared equally (1/23) |
Targent Inc.* |
Spectrum Pharmaceuticals Inc. (SPPI) |
Spectrum acquired the oncology assets of Targent, including levofolinic acid, for which an NDA has been filed |
Targent got 600,000 Spectrum shares, which were valued at about $3M; Targent could receive another 650,000 shares, as well as cash payments, in the deal (3/20) |
TranXenoGenIn |
Advanced Cell Technology Inc. (OTC BB:ACTC) |
Advanced Cell got rights to technology for somatic cell reprogramming |
Advanced Cell had gained an option to the patents in 2005; terms of the exclusive license were not disclosed (4/3) |
Tripos Inc. (TRPS) |
Cara Therapeutics Inc.* |
Tripos will provide chemistry services to support discovery programs at Cara |
The work will be done by Tripos Discovery Research Ltd. in the UK; terms were not disclosed (3/22) |
Valera |
Anthra Pharmaceuticals Inc.* |
Valera acquired Valstar, an anthracyline derivative indicated for treating certain bladder cancers |
The product has been off the market since about 2002, when Anthra went out of business; details on the acquisition were not disclosed (4/3) |
Zygogen LLC* |
DanioLabs Ltd.* (UK) |
DanioLabs got rights to use Zygogen's Z-Tag technology for internal drug screening |
Zygogen is entitled to license and royalty payments under the nonexclusive deal (4/4) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
# Item occurred before the time frame of this chart but was not included in the previous chart. | |||
Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange. |